Insulet Corporation Announces Pricing of Public Offering

BEDFORD, MA -- Insulet Corporation (NASDAQ: PODD) announced the pricing of its public offering of 6,000,000 shares of common stock at $10.25 per share. Insulet has granted the underwriters an option to purchase up to an additional 900,000 shares of common stock to cover any over-allotments. Insulet currently expects to use the net proceeds of this offering for general corporate purposes, which may include the repayment of certain outstanding debt obligations.

J.P. Morgan Securities Inc. is acting as sole book-running manager of the offering and Canaccord Adams Inc. and JMP Securities LLC are acting as co-managers of the offering.

The offering is being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission. This press release does not constitute an offer to sell or a solicitation of an offer to buy securities nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus supplement and accompanying prospectus may be obtained by contacting Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717; or by calling (681) 254-1735.

About Insulet Corporation

Insulet Corporation is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use parts with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. Founded in 2000, Insulet is based in Bedford, MA.